Jiang G, Qiu W, Deluca PP. Preparation and in vitro/in vivo evaluation of insulin-loaded poly (acryloyl-hydroxyethyl starch)-PLGA composite microspheres.Pharm Res. 2003;20:452–459.
Hildebrand GE, Tack JW. Microencapsulation of peptides and proteins.Int J Pharm. 2000;196:173–176.
Haeckel S, Sachse S, Albayrak C, Müller RH. Preparation and characterization of insulin-loaded microcapsules produced by the induced phase separation method. In: Proceedings of the World Meeting, Association of Industrial Galenique Pharmacy/Association of Primate Veterinarians; May 25–28, 1998; Paris, France. 1998. 507–508.
Wall DA. Pulmonary absorption of peptides and proteins.Drug Deliv. 1995;2:1–20.
Stanley SD. Delivery of peptide and non-peptide drugs through the respiratory tract.Pharm Sci Tech Today. 1999;12:450–459.
Niven RW. Delivery of biotherapeutics by inhalation aerosol.Crit Rev Ther Drug Carrier Syst. 1995;12:151–231.
Patton JS, Trinchero P, Platz RM. Bioavailability of pulmonary delivered peptide and protein: interferon alpha, calcitonin and parathyroid hormones.J Control Release. 1994;28:79–85.
Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery.Science. 1997;276:1868–1871.
Berelowitz M, Becker G. Inhaled insulin: clinical pharmacology and clinical study results.Respir Drug Deliv. 2000;7:151–154.
Clauson PG, Balent B, Okikawa J, et al. PK-PD of four different doses of pulmonary insulin delivered with AERx Diabetes management system.Respir Drug Deliv. 2000;7:155–161.
Adjei A, Hui J, Finley R, Lin T, Fort F. Pulmonary bioavailability of leuprolide acetate following multiple dosing to beagle dogs: some pharmacokinetic and pre-clinical issues.Int J Pharm. 1994;107:57–66.
Garber RA, Cappelleri JC, Kourides IA, Gelgend RA, Chandler LP, Gorkin L. Improved patient satisfaction with inhaled insulin in subjects with Type I diabetes mellitus: results from a multi-center randomized controlled trial.Diabetes. 1999;48:A13.
Ganderton D. Targeted delivery of inhaled drugs: current challenges and future trends.J Aerosol Med. 1999;12:3–8.
Saari M, Vidgren MT, Koskinen MO, Turjanmaa VMH, Nieminen MM. Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers.Int J Pharm. 1999;181:1–9.
Waldrep JC, Gilbert BE, Knight CM, et al. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety.Chest. 1997;111:316–323.
Kimelberg HK, Mayhew EG. Properties and biological effects of liposomes and their uses in pharmacology and toxicology.CRC Crit Rev Toxicol. 1978;6:25–79.
Szoka F, Papahadjopoulos D. Liposomes: preparation and characterization. In: Knight CG, ed.Liposomes: From Physical Structure to Therapeutic Applications. New York, NY: Elsevier/North-Holland Biomedical Press; 1981:51–82.
Poznansky MJ, Juliano RL. Biological approaches to the controlled delivery of drugs: a critical review.Pharmacol Rev. 1984;36:277–336.
Knight CG.Liposomes: From Physical Structure to Therapeutic Applications. New York, NY: Elsevier/North-Holland Biomedical Press; 1981.
Akwete LA, Hsu L. Leuprolide and other LH-RH analogues in stability and characterization of protein and peptide drugs: case histories. In: Wang YJ, Pearlman R, eds.Formation, Characterization, and Stability of Protein Drugs. New York, NY: Plenum Press; 1993:159–199.
Enna SJ, Schanker LS. Absorption of drugs from the rat lung.Am J Physiol. 1972;223:1227–1231.
Poulain FR, Allen L, Williams MC, Hamilton RL, Hawgood S. Effects of surfactant apolipoproteins on liposome structure: implications for tubular myelin formation.Am J Physiol. 1992;262:L730-L739.